Today's process patent filing is a tangible, value-accretive step in TheraCryf's IP strategy. It extends potential commercial exclusivity for Ox-1 to 2046, raises the barrier to generic competition, and enhances the asset's attractiveness to potential partners: all at a point in the programme where the company is closing in on a material clinical inflection. We see three near-term catalysts for the stock: (1) Completion of pre-clinical programme and regulatory submissions for FIM studies (H2 2026 target); (2) Potential partnering discussions or term sheet announcements as clinical readiness approaches and (3) Progress updates on the broader patent estate and any further IP strengthening actions. We reiterate our BUY stance. The risk/reward at current levels appears attractive for investors willing to accept the binary nature of biotech development risk, underpinned by a fully funded programme, a strengthening IP moat, and a clearly articulated near-term clinical and commercial roadmap
